On November 26, 2024, BrightSpring Health Services announced that its specialty pharmacy partner, Onco360®, has been selected as the national pharmacy partner for multiple newly approved medications. These drugs are designed to treat advanced cancers and blood diseases, expanding the available care options for patients.
BrightSpring's President and CEO, Jon Rousseau, stated that Onco360 is rapidly bringing innovative medicines and treatments to market to improve the lives of patients with once untreatable, rare diseases. This partnership underscores Onco360's role in distributing breakthrough therapies for life-threatening conditions.
Onco360, recognized as the nation’s leading independent Oncology Pharmacy, will facilitate access to these critical medications. This strategic collaboration is expected to strengthen BrightSpring's presence in the high-growth specialty pharmacy market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.